Scantox Group has released the 2023 Annual Report today. It highlights the many activities our company has done over the year to shape the future of a business that in so many ways contribute to improve lives worldwide through the development of new drugs and treatments. Martin Amtoft-Christensen, CFO Scantox Group : ”We are pleased … Read more
2 April 2024 — Today Scantox, together with its majority owner Impilo, finalized the acquisition of QPS Neuropharmacology, a leading drug discovery CRO specialized in neurodegenerative, rare diseases and mental disorders. The company, as of today integrated into the Scantox Group as Scantox Neuro, is well recognized for its high-quality services that are deeply scientifically rooted and … Read more
As the Society of Toxicology (SOT) Annual Meeting approaches, biopharmaceutical companies have a prime opportunity to engage with industry leaders and explore innovative solutions to advance drug development initiatives. This year, the team at Scantox extends a warm invitation to all attendees to stop by our booth at SOT Week from March 10th to 14th … Read more
30th November 2023 — Today Scantox, together with its majority owner Impilo, has agreed to acquire the neuropharmacology division of QPS Austria GmbH (“QPS Neuro” or “the Company”) ultimately owned by QPS Holdings LLC. QPS Neuro is a leading drug discovery Contract Research Organization (CRO) that specializes in neurodegenerative, rare diseases and mental disorders. The Company … Read more
Scantox A/S (“Scantox”) announces the acquisition of Solural Pharma (“Solural”) in Denmark. Scantox is the leading Nordic GLP-compliant pre-clinical contract research organization (“CRO”), headquartered in Denmark and since 2021 owned by Impilo. Solural has strong expertise in all aspects of formulation development, GMP manufacturing and packaging to support phase 1 & 2 clinical trials. Solural … Read more
November 8th – Scantox Group, a leading provider of nonclinical services in Europe, has named Morten Fjordholt as Sr. Business Development Director with the overall responsibility of growing sales within toxicology and lab services and fostering positive relationships with current and prospective clients. Morten Fjordholt is an experienced Molecular Biologist and pharmaceutical Toxicologist with over two … Read more
31 August 2023 — Scantox A/S (“Scantox” or the “Company”), the leading Nordic GLP-compliant pre-clinical contract research organization (“CRO”), headquartered in Denmark and since 2021 owned by Impilo, is pleased to announce the acquisition of Q&Q Labs AB located in Gothenburg, Sweden (“Q&Q”). Q&Q is a leading provider of tailor-made bioanalytical services and brings a … Read more
Scantox Group is one of this year’s proud nominees to the title ‘Company of the Year 2022’ in the Køge area in Denmark where our HQ is located. Three companies are nominated for all having done an outstanding effort to support local initiatives in the past year. The winner will be announced in January at … Read more
Scantox A/S is pleased to announce the acquisitions of two Swedish companies.
Scantox A/S is pleased to announce the acquisitions of two Swedish companies.
